sábado, 29 de enero de 2011

Roche / Novartis: No debo ir a Davos...No debo ir a Davos...No debo ir a Davos...

Todos los años, por estas fechas, ritualmente los más ricos del mundo, bien protegidos, se reunen en Davos. Celebran lo que pomposamente llaman World Economic Forum Annual Meeting.(Imagen Reuters)

La participación es restringida a:

  • Chief executives of the world's leading global businesses, representing the Forum’s 1,000 Member companies
  • Politicians from the G20 and other key countries – including over 30 heads of state and government
  • The heads of all major international organizations
  • The chairs of the 72 Global Agenda Councils, representing a network of over 1,200 experts
  • Representatives from civil society stakeholder groups
  • Media leaders representing the top news organizations from around the world
  • Young Global Leaders
  • Social Entrepreneurs
  • Technology Pioneers
  • Spiritual and cultural leaders

El lema de esta edición es Reglas compartidas para la nueva realidad...

Así, tal como suena...

Reglas para quién...?

No se cuidan ni en los detalles...

Pero no están sólos...Greenpeace Suiza y Declaración de Berna aprovechan la ocasión para hacer entrega de los premios Public Eye Awards 2011 en reconocimiento a las compañías que mas daño hacen al planeta.

"Whether exploitative working conditions, environmental sins, intentional disinformation, or other disregards of corporate social responsibility: At the forefront of the World Economic Forum (WEF) in late January, the most evil offenses appear on the shortlist of the Public Eye Awards 2011. And those firms placed in the pillory will feel the heat: Our renowned naming&shaming awards shine an international spotlight on corporate scandals and thereby help focused NGO campaigns succeed. This year's categories are the GLOBAL award (chosen by an internal panel of experts) and the PEOPLE'S award (chosen by YOU and thousands of other online activists)."

Un "habitué" en Davos es Daniel Vasella (Presidente de Novartis). Seguro tambien lo es Severin Schwan (Ceo de Roche). (Juegan en casa...)

Con agenda tan ocupada en los profusos temas de las reuniones seguro "pasaron por alto" (es decir"pasaron de...) asistir a la entrega de los premios (Public Eye Awards) a que fueron merecedores en ediciones anteriores.

Ranking/Hall of shame.

Roche en 2010 por:

China proudly proclaims that roughly 10,000 organ transplants take place annually in its clinics. However because of Chinese culture, there are few voluntary organ donations from the population. Where do all the transplanted organs come from? At the end of 2008, the Chinese vice health minister admitted in a medical journal that more than 90 percent of all transplanted organs come from executed prisoners. The World Medical Association and other international organizations unanimously oppose the transplantation of prisoner organs on ethical grounds. Even when a prisoner supposedly consents to an organ donation, such consent while imprisoned cannot be considered of one’s own free will. The drug Cell Cept, from the Roche pharmaceutical firm, prevents the rejection of transplanted organs. Roche markets the drug in China despite the country’s unethical transplantation practices. The company has even been producing Cell Cept in China for several years. Furthermore, Roche is currently studying the drug’s effects in two studies with some 300 transplanted organs in Chinese clinics. Roche claims to have no information regarding the origins of the transplanted organs. The firm must therefore immediately halt these studies since it cannot ensure that none of the organs come from prisoners.


Novartis en 2007 por:

In 2003, the Patent Office in Chennai (formerly Madras), India, awarded temporary exclusive marketing rights (EMR) for the commercialization of the cancer drug Imatinib Mesylate (Glivec®) to the Swiss pharmaceutical company Novartis. This led to a halt in production of generic equivalents in India. Since generic versions costing one-tenth as much as Glivec® could no longer be sold, thousands of patients worldwide lost access to an affordable drug that delays the advancement of leukemia.

In January 2006, owing to a protest by the Cancer Patients Aid Association (CPAA), the Chennai Patent Office denied Novartis patent application for Glivec®, and at the same time canceled the EMR. The production of generics could therefore restart. Novartis opposes the decision, and is doing everything it can to regain the EMR.


No hay comentarios: